How many Cochlear shares do I need to buy for $10,000 of passive income?

The dividend maths on this fallen ASX healthcare heavyweight.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Working out how many Cochlear Ltd (ASX: COH) shares you need for $10,000 of passive income is simple maths, but the answer might catch you off guard.

Cochlear is the world's leading maker of implantable hearing solutions, holding around 60% of the global cochlear implant market.

For years, the company was a dependable compounder that quietly rewarded patient shareholders.

The past 12 months, however, have tested even its most loyal investors.

An older woman tries to listen by cupping her ear.

Image source: Getty Images

The dividend maths for Cochlear shares

Cochlear pays two dividends to shareholders each year.

Lately, those payments have added up to an annual dividend of $4.30 per share.

The most recent interim dividend of $2.15 was franked at 85%, which adds a further tax benefit for many holders.

To generate $10,000 in annual passive income, including franking credits, the calculation is straightforward.

You simply divide $10,000 by the grossed-up dividend of about $5.87 (the $4.30 cash payout plus roughly $1.57 in franking credits).

That works out to roughly 1,705 Cochlear shares.

At current share prices of around $118, those shares would set you back close to $201,190.

That is a serious amount of capital for most everyday investors to commit, and it is also a reminder that Cochlear has never really been an income stock at heart.

At current prices, the shares offer a gross dividend yield of about 3.6%, although franking credits sweeten that headline return a little further at tax time.

Why have Cochlear shares fallen so far?

The dividend is only half the story here.

Cochlear shares have dropped heavily over the past year, one of the reasons why Cochlear's dividend yield looks unusually generous now.

The stock currently trades far below its 52-week high of $319.56, largely due to a run of disappointing news from the company itself.

Recent earnings in focus

Cochlear reported its half-year results for the six months to 31 December 2025 back in February.

In these results, sales revenue came in at about $1.17 billion, broadly flat on the prior corresponding period. Statutory net profit fell a nasty 21% to $161.5 million, and underlying net profit slipped 9% to $195 million.

The weaker result was driven largely by the costly rollout of the new Nexa implant system, while competitive discounting from rivals chipped away at market share.

Management chose to hold the interim dividend steady rather than lift it, a call that speaks volumes about the year ahead.

Investors will get their next major update when Cochlear reports its full-year FY26 results on 18 August 2026.

Are Cochlear shares worth it for the income?

That is the real question for income-focused investors.

Cochlear is a high-quality business with a wide competitive moat, but its dividend yield is modest next to the ASX banks or Telstra Group Ltd (ASX: TLS).

An investor chasing pure income could reach $10,000 with far less capital elsewhere.

The appeal of Cochlear shares has always been growth, not yield, and anyone buying today is really paying for a long-term recovery story.

In other words, the dividend is a bonus, not the main event.

Foolish Takeaway

You would need roughly 1,705 Cochlear shares to earn $10,000 in annual passive income once franking credits are included.

At current prices, that means an outlay of close to $201,000.

For most investors, Cochlear shares make more sense as a growth holding than a pure income one.

On the growth front, Cochlear's looming FY26 result will tell us whether the recovery is finally on track.

Until then, the passive income case remains an expensive one to make.

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists analysing results on a computer screen.
Healthcare Shares

3 ASX healthcare shares to buy with 25% to 100% upside as sector rebound races higher

After slumping to a 9-year low on 3 June, healthcare shares have rallied by an extraordinary 42%.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Are CSL shares still cheap after almost doubling since June?

The healthcare giant is no longer dirt cheap, but let's find out if the current valuation leaves room for long-term…

Read more »

Buy the dip written on a yellow sign.
Broker Notes

Down 43%! 4 reasons to buy the BIG dip in Pro Medicus shares today

A leading expert believes Pro Medicus shares are well-place to rebound.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL led the ASX healthcare shares rebound. Can it continue?

The rebound of healthcare stocks looks promising, but proving the recovery is real remains.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Ingenia Communities Group rejects takeover offer, backs growth strategy

Ingenia Communities Group has rejected a takeover offer from Warburg Pincus, reaffirming its strategy and Peet acquisition plans.

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Healthcare Shares

CSL shares are up 94% from their low. What are brokers forecasting next?

Can CSL’s improving fundamentals justify the optimism now priced into shares?

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Dividend Investing

Looking to bank the upcoming CSL dividend? You better hurry!

Not only have CSL shares surged 91% since June, but the final dividend payout is still up for grabs. Though…

Read more »

a group of surgeons in full surgery dress including masks, gloves and head coverings stands together with arms folded and smiling eyes as if happy with the outcome of their efforts.
Healthcare Shares

Top 3 ASX healthcare shares to buy after a brutal year

Three very different ways to back healthcare.

Read more »